COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries.
Adolescent
Adult
Aged
COVID-19
/ prevention & control
COVID-19 Vaccines
/ therapeutic use
Child
Child, Preschool
Female
Health Knowledge, Attitudes, Practice
Humans
Intention
Internationality
Middle Aged
Mothers
/ psychology
Patient Acceptance of Health Care
/ psychology
Pregnancy
Pregnancy Complications, Infectious
/ prevention & control
Pregnant Women
/ psychology
SARS-CoV-2
Young Adult
COVID-19
Pregnancy
Vaccination
Vaccine acceptance
Vaccine confidence
Journal
European journal of epidemiology
ISSN: 1573-7284
Titre abrégé: Eur J Epidemiol
Pays: Netherlands
ID NLM: 8508062
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
02
02
2021
accepted:
05
02
2021
pubmed:
3
3
2021
medline:
7
4
2021
entrez:
2
3
2021
Statut:
ppublish
Résumé
With the development of multiple effective vaccines, reducing the global morbidity and mortality of COVID-19 will depend on the distribution and acceptance of COVID-19 vaccination. Estimates of global vaccine acceptance among pregnant women and mothers of young children are yet unknown. An understanding of the challenges and correlates to vaccine acceptance will aid the acceleration of vaccine administration within these populations. Acceptance of COVID-19 vaccination among pregnant women and mothers of children younger than 18-years-old, as well as potential predictors, were assessed through an online survey, administered by Pregistry between October 28 and November 18, 2020. 17,871 total survey responses from 16 countries were obtained. Given a 90% COVID-19 vaccine efficacy, 52.0% of pregnant women (n = 2747/5282) and 73.4% of non-pregnant women (n = 9214/12,562) indicated an intention to receive the vaccine. 69.2% of women (n = 11,800/17,054), both pregnant and non-pregnant, indicated an intention to vaccinate their children. Vaccine acceptance was generally highest in India, the Philippines, and all sampled countries in Latin America; it was lowest in Russia, the United States and Australia. The strongest predictors of vaccine acceptance included confidence in vaccine safety or effectiveness, worrying about COVID-19, belief in the importance of vaccines to their own country, compliance to mask guidelines, trust of public health agencies/health science, as well as attitudes towards routine vaccines. COVID-19 vaccine acceptance and its predictors among women vary globally. Vaccination campaigns for women and children should be specific for each country in order to attain the largest impact.
Identifiants
pubmed: 33649879
doi: 10.1007/s10654-021-00728-6
pii: 10.1007/s10654-021-00728-6
pmc: PMC7920402
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
197-211Références
Johns Hopkins Coronavirus Resource Center. COVID-19 dashboard. https://coronavirus.jhu.edu/map.html . Accessed 26 Dec 26 2020.
World Bank. COVID-19 to add as many as 150 million extreme poor by 2021 World Bank. https://www.worldbank.org/en/news/press-release/2020/10/07/covid-19-to-add-as-many-as-150-million-extreme-poor-by-2021 . Accessed 22 Dec 2020.
Diseases TLI. The intersection of COVID-19 and mental health. Lancet Infect Dis. 2020;20:1217.
doi: 10.1016/S1473-3099(20)30797-0
Pfizer. Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from phase 3 study. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against . Accessed 22 Dec 2020.
Moderna announces primary efficacy analysis in Phase 3 COVE study for its COVID-19 vaccine candidate and filing today with U.S. FDA for emergency use authorization. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study . Accessed 22 Dec 2020
Zimmer C, Corum J, Wee S. Coronavirus vaccine tracker. https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html . Accessed 24 Dec 2020.
Bloom B, Nowak G, Orenstein W. When will we have a vaccine? Understanding questions and answers about covid-19 vaccination. N Engl J Med. 2020;383:2202–4.
doi: 10.1056/NEJMp2025331
World Health Organization. Ten health issues WHO will tackle this year. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019 . Accessed 22 Dec 2020.
SAGE Working Group on Vaccine Hesitancy. Report of the SAGE Working Group on Vaccine Hesitancy. https://www.who.int/immunization/sage/meetings/2014/october/SAGE_working_group_revised_report_vaccine_hesitancy.pdf . Accessed 22 Dec 2020.
Perlis R, Lazer D, Ognayanova K, Druckman BM, Santillana M, et al. State of the nation: a 50–state COVID-19 survey report #9: Will Americans vaccinate themselves and their children against COVID-19? https://covidstates.org/reports/ . Accessed 24 Dec 2020.
Lazarus J, Ratzan S, Palayew A, Gostin L, Larson H, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2020;27:1–4.
Barello S, Nania T, Dellafiore F, Graffigna G, Caruso R. ‘Vaccine hesitancy’ among university students in Italy during the COVID-19 pandemic. Eur J Epidemiol. 2020;35:781–3.
doi: 10.1007/s10654-020-00670-z
Ellington S, Strid P, Tong V, Woodworth K, Galang R, Zambrano L, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22–June 7, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:769–75.
doi: 10.15585/mmwr.mm6925a1
Collin J, Byström E, Carnahan A, Ahrne M. Public Health Agency of Sweden’s brief report: pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2 infection in intensive care in Sweden. Acta Obstet Gynecol Scand. 2020;99:819–22.
doi: 10.1111/aogs.13901
Delahoy MJ, Whitaker M, O’Halloran A, Chai SJ, Kirley PD, Alden N, et al. Characteristics and maternal and birth outcomes of hospitalized pregnant women with laboratory-confirmed COVID-19–COVID-NET, 13 states, March 1–August 22, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1347–54.
doi: 10.15585/mmwr.mm6938e1
Panagiotakopoulos L, Myers TR, Gee J, Lipkind HS, Kharbanda EO, Ryan DS, et al. SARS-CoV-2 infection among hospitalized pregnant women: reasons for admission and pregnancy characteristics—eight US health care centers, March 1–May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1355–9.
doi: 10.15585/mmwr.mm6938e2
Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22–October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1641–7.
doi: 10.15585/mmwr.mm6944e3
Mehta NS, Mytton OT, Mullins EW, Fowler TA, Falconer CL, Murphy OB, et al. SARS-CoV-2 (COVID19): What do we know about children? A systematic review. Clin Infect Dis. 2020;71:2469–79.
doi: 10.1093/cid/ciaa556
Ludvigsson J. Children are unlikely to be the main drivers of the COVID-19 pandemic—a systematic review. Acta Paediatr. 2020;109:1525–30.
doi: 10.1111/apa.15371
Pregistry. International registry of Coronavirus exposure in pregnancy. https://corona.pregistry.com . Accessed 25 Dec 2020.
ClinicalTrials.gov [Internet]. Bethesda (MD): national library of medicine (US). 2020 Dec 24 - identifier NCT04366986, international registry of coronavirus (COVID-19) exposure in pregnancy (IRCEP). Available from: https://clinicaltrials.gov/ct2/show/NCT04366986 .
Harrison EA, Wu JW. Vaccine confidence in the time of COVID-19. Eur J Epidemiol. 2020;35:325–30.
doi: 10.1007/s10654-020-00634-3
Larson H, Cooper L, Eskola J, Katz S, Ratzan S. Addressing the vaccine confidence gap. Lancet. 2011;378:526–35.
doi: 10.1016/S0140-6736(11)60678-8
Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J. Vaccine hesitancy: an overview. Hum Vaccin Immunother. 2013;9:1763–73.
doi: 10.4161/hv.24657
Larson HJ, Jarrett C, Eckersberger E, Smith DMD, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007–2012. Vaccine. 2014;32:2150–9.
doi: 10.1016/j.vaccine.2014.01.081
De Figueiredo A, Simas C, Karafillakis E, Paterson P, Larson HJ. Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study. Lancet. 2020;396:898–908.
doi: 10.1016/S0140-6736(20)31558-0
Morimoto A, Ueda Y, Egawa-Takata T, Yagi A, Terai Y, Ohmichi M, et al. Effect on HPV vaccination in Japan resulting from news report of adverse events and suspension of governmental recommendation for HPV vaccination. Int J Clin Oncol. 2015;20:549–55.
doi: 10.1007/s10147-014-0723-1
Dada S, McKay G, Mateus A, Lees S. Lessons learned from engaging communities for Ebola vaccine trials in Sierra Leone: reciprocity, relatability, relationships and respect (the four R’s). BMC Public Health. 2019;19:1665.
doi: 10.1186/s12889-019-7978-4
Randall T, Sam C, Tartar A, Cannon C. More than 5.6 million shots given: COVID-19 Vaccine Tracker. https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/ . Accessed 30 Dec 2020.
Hamel L, Kirzinger A, Muñana C, Brodie M. KFF COVID-19 vaccine monitor: December 2020. https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-december-2020/ . Accessed 30 Dec 2020.